End-to-End Antibody Discovery: Yeast Display, Automation, AI, and Multispecifics

​Most of the human surfaceome and secretome still lack monoclonals validated for anything beyond western blot, and therapeutic pipelines remain crowded around a handful of targets.

​The team at the Institute of Protein Innovation have built an integrated platform that pushes antibody and nanobody discovery past 200 targets per year, combining yeast surface display, laboratory automation, and AI-guided clone triage.

​They will walk through the architecture of the platform, including antigen production, library sorting, single-clone characterization and validation, and also the design choices that make this throughput sustainable rather than heroic.

​They will also show how the same pipeline supports rational engineering of new functions, including biparatopic antibodies that crosslink cell-surface receptors to drive axon growth. The goal is to give the audience a concrete blueprint for running discovery at this scale, and an honest view of where automation and AI actually move the needle.

​This discussion will be hosted and moderated by MiLaboratories, the creators of the leading biologics discovery software.